Обзорная статья

Triptans and CGRP blockade – impact on the cranial vasculature

Silvia BenemeiHealth Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Viale Pieraccini 6, 50134, Florence, Italy. [email protected]Francesca CorteseDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, ItalyAlejandro Labastida‐RamírezDept Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, The NetherlandsFrancesca MarcheseChild Neuropsichiatry Unit, University of Palermo, Palermo, ItalyLanfranco PellesiMedical Toxicology Headache and Drug Abuse Center, University of Modena and Reggio Emilia, Modena, ItalyMichele RomoliNeurology Clinic, University Hospital of Perugia, Perugia, ItalyAnne Luise Haulund VollesenRigshospitaletChristian LamplDepartment of Neurogeriatric Medicine, Headache Medical Center Linz, Linz, AustriaMessoud AshinaDanish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

2017en

ABI

Аннотация

The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.

Перевод пока недоступен

Идентификаторы

DOI: 10.1186/s10194-017-0811-5

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar